Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer
HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products,…
Pharmaceuticals, Biotechnology and Life Sciences
HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products,…
MALVERN, Pa.–(BUSINESS WIRE)–Encore Dermatology Inc. announced today that it has acquired rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05%, as well…
Biotech creating a new therapy for hot flashes in breast cancer patients launches clinical trials across United States ATLANTA–(BUSINESS WIRE)–Clinical…
Centogene has appointed Dr. Flemming Ornskov to the Supervisory Board and he has also been elected Non-Executive Chairman, effective April 1, 2019.
Johnson & Johnson has bought Auris Health, Inc. for about $3.4 billion in cash, with additional payments of up to $2.35 billion, in the aggregate, which may be payable upon reaching certain predetermined milestones, JJ said in a statement Monday.
UK-based contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has announced its acquisition of CiVentiChem’s US facility located in Cary, North Carolina, US.
Novartis got approval from the China Health Authority NMPA for
Cosentyx, its the first-in-class interleukin-17A inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Allergan and Molecular Partners revealed Tuesday the topline safety results from MAPLE, study which enrolled 123 age-related Neovascular Macular Degeneration (nAMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process, which showed lower incidence and type of IOI.
AUSTIN, Texas & NEW YORK–(BUSINESS WIRE)–CDISC will develop the first global, non-proprietary clinical data standards for Crohn’s disease with a…
DUBLIN–(BUSINESS WIRE)–The “Retinoblastoma Treatment Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering.…